We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · November 23, 2021

Amphilimus- vs Zotarolimus-Eluting Stents in Patients With Diabetes and Coronary Artery Disease

European Heart Journal


Additional Info

Disclosure statements are available on the authors' profiles:

European Heart Journal
Amphilimus- versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease (SUGAR trial)
Eur Heart J 2021 Nov 04;[EPub Ahead of Print], R Romaguera, P Salinas, J Gomez-Lara, S Brugaletta, A Gómez-Menchero, MA Romero, S García-Blas, R Ocaranza, P Bordes, MJ Kockar, N Salvatella, VA Jiménez-Díaz, M Alameda, R Trillo, DH Lee, P Martín, M López-Benito, A Freites, V Pascual-Tejerino, F Hernández-Hernández, B García Del Blanco, M Mohandes, F Bosa, E Pinar, G Roura, J Comin-Colet, A Fernández-Ortiz, C Macaya, X Rossello, M Sabate, SJ Pocock, JA Gómez-Hospital

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading